Ancer Immunotherapy News Today

Activated T cells that carry a certain marker protein on their surface are controlled by natural killer (NK) cells, another cell type of the immune system.

New quarterly earnings reports offer insight into how the companies are preparing to potentially lose significant sources of revenue

Two siblings who have the only known mutations in a key gene anywhere in the world have helped scientists gain new insights that could help progress the search for new treatments in type 1 diabetes.

Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients' immune systems fight back against cancer, according to a study by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

Older people may be at greater risk of developing pancreatic cancer and have poorer prognoses because of age-related changes in cells in the pancreas called fibroblasts, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins Bloomberg School of Public Health and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

Cancer Immunotherapy Stocks to Watch (NASDAQ: ONCY) (TSX: ONC) (Nasdaq: CADL) (Nasdaq: BNTX) (NASDAQ: IMTX)

Dublin, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The

Immunotherapies using engineered T cells have ushered in a new era in cancer treatment, but they have their limits. They may cause side effects or stop working, and they do not work at all against 90% of cancers.

(Reuters) -Merck & Co reported better-than-expected fourth-quarter results on Thursday on strong sales of its cancer immunotherapy Keytruda, now the world's biggest selling prescription medicine. Keytruda sales rose 21% to $6.6 billion as the company was able to increase use of the drug in earlier stage cancers, topping analyst forecasts of $6.5 billion. For the full year, Keytruda generated $25 billion, surpassing sales of AbbVie's blockbuster arthritis drug Humira at its peak.

Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The